Targeting phosphoinositide 3-kinase γ to fight inflammation and more

Summary

The family of class I phosphoinositide-3-kinase (PI3K) is composed of four lipid kinases involved at multiple levels in innate and adaptive immune responses. Class I PI3Ks are divided into two subclasses, IA and IB, sharing a similar catalytic core. Whereas class IA PI3Ks are primarily activated by receptor tyrosine kinases, the unique element of class IB PI3K (PI3Kγ) is activated by G protein coupled receptors (GPCRs), like chemokine receptors. PI3Kγ is mainly expressed in leukocytes where it plays a significant role in chemotaxis. Here, we report recent advances in the analysis of the role of PI3Kγ in leukocytes and in endothelial cells. Results, derived from studies based on both pharmacological and genetic approaches, confirm PI3Kγ as an attractive target for drug discovery. PI3Kγ specific inhibition has gained increasing attention for the treatment of allergic, autoimmune and inflammatory diseases. Development of inhibitors has already provided series of hits, whose efficacy is currently under scrutiny worldwide.

Keywords

Inflammation - leukocyte trafficking / recruitment - signal transduction - endothelial cells

• References

• 1 Whitman M, Downes CP, Keeler M. et al. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 1988; 332: 644-646.
• 2 Ridley AJ, Schwartz MA, Burridge K. et al. Cell migration: integrating signals from front to back. Science 2003; 302: 1704-1709.
• 3 Wymann MP, Marone R. Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Curr Opin Cell Biol 2005; 17: 141-149.
• 4 Medina-Tato DA, Ward SG, Watson ML. Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond. Immunology 2007; 121: 448-461.
• 5 Costa C, Barberis L, Ambrogio C. et al. Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase gamma. Proc Natl Acad Sci USA 2007; 104: 14354-14359.
• 6 Vanhaesebroeck B, Leevers SJ, Ahmadi K. et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2001; 70: 535-602.
• 7 Shinohara M, Terada Y, Iwamatsu A. et al. SWAP-70 is a guanine-nucleotide-exchange factor that mediates signalling of membrane ruffling. Nature 2002; 416: 759-763.
• 8 Welch HC, Coadwell WJ, Ellson CD. et al. P-Rex1, a PtdIns(3,4,5)P3– and Gbetagamma-regulated guanine-nucleotide exchange factor for Rac. Cell 2002; 108: 809-821.
• 9 Parry RV, Riley JL, Ward SG. Signalling to suit function: tailoring phosphoinositide 3-kinase during T-cell activation. Trends Immunol 2007; 28: 161-168.
• 10 Hirsch E, Lembo G, Montrucchio G. et al. Signaling through PI3Kgamma: a common platform for leukocyte, platelet and cardiovascular stress sensing. Thromb Haemost 2006; 95: 29-35.
• 11 Finan PM, Thomas MJ. PI 3-kinase inhibition: a therapeutic target for respiratory disease. Biochem Soc Trans 2004; 32: 378-382.
• 12 Ward S, Sotsios Y, Dowden J. et al. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem Biol 2003; 10: 207-213.
• 13 Rommel C, Camps M, Ji H. PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?. Nat Rev Immunol 2007; 7: 191-201.
• 14 Bi L, Okabe I, Bernard DJ. et al. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J Biol Chem 1999; 274: 10963-10968.
• 15 Bi L, Okabe I, Bernard DJ. et al. Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm Genome 2002; 13: 169-172.
• 16 Ruckle T, Schwarz MK, Rommel C. PI3Kgamma inhibition: towards an ‘aspirin of the 21st century'?. Nat Rev Drug Discov 2006; 5: 903-918.
• 17 Hirsch E, Katanaev VL, Garlanda C. et al. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 2000; 287: 1049-1053.
• 18 Hannigan M, Zhan L, Li Z. et al. Neutrophils lacking phosphoinositide 3-kinase gamma show loss of directionality during N-formyl-Met-Leu-Phe-induced chemotaxis. Proc Natl Acad Sci USA 2002; 99: 3603-3608.
• 19 Jones GE, Prigmore E, Calvez R. et al. Requirement for PI 3-kinase gamma in macrophage migration to MCP-1 and CSF-1. Exp Cell Res 2003; 290: 120-131.
• 20 Crackower MA, Oudit GY, Kozieradzki I. et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 2002; 110: 737-749.
• 21 Patrucco E, Notte A, Barberis L. et al. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 2004; 118: 375-87.
• 22 Vecchione C, Patrucco E, Marino G. et al. Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kgamma. J Exp Med 2005; 201: 1217-1228.
• 23 Madeddu P, Kraenkel N, Barcelos LS. et al. Phosphoinositide 3-kinase gamma gene knockout impairs postischemic neovascularization and endothelial progenitor cell function. Arterioscler Thromb Vasc Biol. 2007 in press.
• 24 Li Z, Jiang H, Xie W. et al. Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science 2000; 287: 1046-1049.
• 25 Sasaki T, Irie-Sasaki J, Jones RG. et al. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 2000; 287: 1040-1046.
• 26 Condliffe AM, Davidson K, Anderson KE. et al. Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 2005; 106: 1432-1440.
• 27 Wymann MP, Sozzani S, Altruda F. et al. Lipids on the move: phosphoinositide 3-kinases in leukocyte function. Immunol Today 2000; 21: 260-264.
• 28 Yum HK, Arcaroli J, Kupfner J. et al. Involvement of phosphoinositide 3-kinases in neutrophil activation and the development of acute lung injury. J Immunol 2001; 167: 6601-6608.
• 29 Thomas PS, Gibson PG, Wang H. et al. The relationship of exhaled nitric oxide to airway inflammation and responsiveness in children. J Asthma 2005; 42: 291-295.
• 30 Lupia E, Goffi A, De Giuli P. et al. Ablation of phosphoinositide 3-kinase-gamma reduces the severity of acute pancreatitis. Am J Pathol 2004; 165: 2003-2011.
• 31 Camps M, Ruckle T, Ji H. et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 2005; 11: 936-943.
• 32 Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997; 9: 10-16.
• 33 Allavena P, Sica A, Vecchi A. et al. The chemokine receptor switch paradigm and dendritic cell migration: its significance in tumor tissues. Immunol Rev 2000; 177: 141-149.
• 34 Del Prete A, Vermi W, Dander E. et al. Defective dendritic cell migration and activation of adaptive immunity in PI3Kgamma-deficient mice. Embo J 2004; 23: 3505-3515.
• 35 Reif K, Okkenhaug K, Sasaki T. et al. Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing. J Immunol 2004; 173: 2236-2240.
• 36 Barber DF, Bartolome A, Hernandez C. et al. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 2005; 11: 933-935.
• 37 Nombela-Arrieta C, Lacalle RA, Montoya MC. et al. Differential requirements for DOCK2 and phosphoinositide-3-kinase gamma during T and B lymphocyte homing. Immunity 2004; 21: 429-441.
• 38 Nombela-Arrieta C, Mempel TR, Soriano SF. et al. A central role for DOCK2 during interstitial lymphocyte motility and sphingosine-1-phosphate-mediated egress. J Exp Med 2007; 204: 497-510.
• 39 Medina-Tato DA, Watson ML, Ward SG. Leukocyte navigation mechanisms as targets in airway diseases. Drug Discov Today 2006; 11: 866-879.
• 40 Weiss-Haljiti C, Pasquali C, Ji H. et al. Involvement of phosphoinositide 3-kinase gamma, Rac, and PAK signaling in chemokine-induced macrophage migration. J Biol Chem 2004; 279: 43273-43284.
• 41 Ferguson GJ, Milne L, Kulkarni S. et al. PI(3)Kgamma has an important context-dependent role in neutrophil chemokinesis. Nat Cell Biol 2007; 9: 86-91.
• 42 Li Z, Hannigan M, Mo Z. et al. Directional sensing requires G beta gamma-mediated PAK1 and PIX alphadependent activation of Cdc42. Cell 2003; 114: 215-227.
• 43 Van Keymeulen A, Wong K, Knight ZA. et al. To stabilize neutrophil polarity, PIP3 and Cdc42 augment RhoA activity at the back as well as signals at the front. J Cell Biol 2006; 174: 437-445.
• 44 Puri KD, Doggett TA, Huang CY. et al. The role of endothelial PI3Kgamma activity in neutrophil trafficking. Blood 2005; 106: 150-157.
• 45 Laffargue M, Calvez R, Finan P. et al. Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function. Immunity 2002; 16: 441-451.
• 46 Hirsch E. Signal transduction in inflammation. Perspective clues from the leukocyte-endothelium interface. Thromb Haemost 2006; 95: 3-4.
• 47 Puri KD, Doggett TA, Douangpanya J. et al. Mechanisms and implications of phosphoinositide 3-kinase delta in promoting neutrophil trafficking into inflamed tissue. Blood 2004; 103: 3448-3456.
• 48 Dimmeler S, Aicher A, Vasa M. et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001; 108: 391-397.
• 49 Potente M, Urbich C, Sasaki K. et al. Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization. J Clin Invest 2005; 115: 2382-2392.
• 50 Urbich C, Knau A, Fichtlscherer S. et al. FOXO-dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial progenitor cells. Faseb J 2005; 19: 974-976.
• 51 Aicher A, Heeschen C, Mildner-Rihm C. et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003; 9: 1370-1376.
• 52 Chen YH, Lin SJ, Lin FY. et al. High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide-related but not oxidative stress-mediated mechanisms. Diabetes 2007; 56: 1559-1568.
• 53 Lainer-Carr D, Brahn E. Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nature clinical practice 2007; 3: 434-442.
• 54 Jain RK, Finn AV, Kolodgie FD. et al. Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization. Nat Clin Pract Cardiovasc Med 2007; 4: 491-502.
• 55 Maus UA, Backi M, Winter C. et al. Importance of phosphoinositide 3-kinase gamma in the host defense against pneumococcal infection. Am J Respir Crit Care Med 2007; 175: 958-966.
• 56 Bruce I, Finan P, Leblanc C. et al. inventors; Novartis AG, assignee. 5-phenylthiazole derivatives and use as PI3 kinase inhibitors. CH patent WO/2003/072557. 2003
• 57 Bloomfield GC, Bruce I, Leblanc C. et al. inventors; Novartis AG, assignee. 5-phenylthiazole derivatives and their use as P13 kinase inhibitors. CH patent WO/2004/078754. 2004
• 58 Bruce I, Cuenoud B, Pilgrim GE. et al. inventors; Novartis AG, assignee. Inhibitors of phosphatidylinositol 3-kinase. CH patent WO/2004/096797. 2004
• 59 Bloomfield GC, Bruce I, Hayler JF. et al. inventors; Novartis AG, assignee. 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (PI3) for the treatment of inflammatory airway diseases. CH patent WO/2005/021519. 2005
• 60 Barvian NC, Kolz CN, Para KS. et al. inventors; Pfizer Inc, assignee. Benzoxazin-3-ones and derivatives thereof as inhibitors of PI3K. USA patent WO/2004/052373. 2004
• 61 Gogliotti RD, Muccioli KL, Para KS. et al. inventors; Pfizer Inc, assignee. Benzoxazines and derivatives thereof as inhibitors of PI3KS. USA patent WO/2004/056820. 2004
• 62 Gogliotti RD, Lee HT, Sexton KE. et al. inventors; Pfizer Inc, assignee. Cycloalkylsulfanyl substituted benzo[B]thiophenes as therapeutic agents. USA patent WO/2004/108714. 2004
• 63 Gogliotti RD, Lee HT, Sexton KE. et al. inventors; Pfizer Inc, assignee. 3-arylsulfanyl and 3-heteroarylsulfanyl substituted benzo[B]thiophenes as therapeutic agents. USA patent WO/2004/108716. 2004
• 64 Gogliotti RD, Lee HT, Sexton KE. et al. inventors; Pfizer Inc, assignee. Tetrazol benzofurancarboxamides with P13K aktivity as therapeutic agents. USA patent WO/2004/108709. 2004
• 65 Rueckle T, Jiang X, Gaillard P. et al. inventors; Serono International SA, assignee. Azolidinone-vinyl fused-benzene derivatives. CH patent WO/2004/007491. 2004
• 66 Quattropani A, Rueckle T, Schwarz M. et al. inventors; Serono International SA, assignee. Thiazole derivatives and use thereof. CH patent WO/2005/068444. 2005
• 67 Rueckle T, Shaw J, Church D. et al. inventors; Serono International SA, assignee. 2-imino-4-(thio) oxo-5-poly cyclovinylazolines for use as P13 kinase ihibitors. CH patent WO/2005/011686. 2005
• 68 Rueckle T, Quattropani A, Pomel V. et al. inventors; Merck Serono International SA, assignee. Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors. CH patent WO/2006/024666. 2006
• 69 Chatham WW, Kimberly RP. Treatment of lupus with corticosteroids. Lupus 2001; 10: 140-147.
• 70 Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003; 2: 473-488.
• 71 Diacovo TG, Hayflick JS, Puri KD. inventors; ICOS Corp, assignee. Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation. USA patent WO/2006/089106. 2006
• 72 Doukas J, Wrasidlo W, Noronha G. et al. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc Natl Acad Sci USA 2006; 103: 19866-19871.